©FabienMalotParis-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices.
ADVERTISEMENT
Paris-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices.